The progressive loss of blood flow to retinal tissue represents one of diabetes' most devastating complications, often culminating in irreversible vision loss. Yet the effectiveness of different injection therapies in halting this damage has remained poorly quantified until now. Advanced imaging technology reveals steroid treatments may offer superior protection compared to the more commonly prescribed anti-VEGF medications.
Researchers tracked 65 diabetic eyes using ultra-widefield fluorescein angiography, measuring precisely how blood-starved retinal areas changed following intravitreal injections. Eyes receiving steroid treatments showed markedly smaller increases in non-perfused areas compared to those getting anti-VEGF therapy or no treatment—just 4.32 square millimeters versus 32.30 and 27.21 square millimeters respectively. More frequent steroid injections correlated with reduced damage to the foveal avascular zone, the critical central vision area. Additionally, each month of delayed treatment corresponded to nearly one additional square millimeter of retinal damage.
This finding challenges current diabetic retinopathy treatment paradigms, where anti-VEGF injections dominate despite limited evidence of their superiority in preserving retinal perfusion. The study suggests steroids' anti-inflammatory properties may more effectively protect retinal vasculature than simply blocking vascular growth factors. However, this single-center retrospective analysis with modest sample sizes requires validation through randomized controlled trials before reshaping clinical practice. Steroid treatments carry distinct side effect profiles including elevated eye pressure and cataract formation, necessitating careful risk-benefit calculations. The research nonetheless provides compelling evidence that treatment choice significantly impacts long-term retinal health outcomes in diabetic patients.